________________________________________________________
____EntRel____
343
2
____Arg1____
216..341
1
#### Text ####
Neither Vitarine nor any of the Springfield Gardens, N.Y., company's officials or employees have been charged with any crimes
##############
____Arg2____
343..503
2
#### Text ####
Vitarine won approval to market a version of a blood pressure medicine but acknowledged that it substituted a SmithKline Beecham PLC product as its own in tests
##############
________________________________________________________
________________________________________________________
____Explicit____
518..522
3,1
#### Text ####
also
##############
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
9..212
0
#### Text ####
Food and Drug Administration spokesman Jeff Nesbit said the agency has turned over evidence in a criminal investigation concerning Vitarine Pharmaceuticals Inc. to the U.S. Attorney's office in Baltimore
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
507..517;523..629
3,0;3,2;3,3
#### Text ####
Mr. Nesbit said the FDA has asked Bolar Pharmaceutical Co. to recall at the retail level its urinary tract antibiotic
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
631..634
4,0,0
#### Text ####
But
##############
#### Features ####
Ot, Comm, Null, Null
689..707
4,1;4,2;4,3;4,4
#### Text ####
the spokesman said
##############
but, Comparison.Contrast
____Arg1____
528..629
3,2,1
#### Text ####
the FDA has asked Bolar Pharmaceutical Co. to recall at the retail level its urinary tract antibiotic
##############
#### Features ####
Ot, Comm, Null, Null
507..527
3,0;3,1;3,2,0;3,3
#### Text ####
Mr. Nesbit also said
##############
____Arg2____
635..687
4,0,1;4,0,2;4,0,3
#### Text ####
so far the company hasn't complied with that request
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
1015..1022
6,1
#### Text ####
earlier
##############
#### Features ####
Wr, Comm, Null, Null
earlier, Temporal.Asynchronous.Succession
____Arg1____
711..967
5,0
#### Text ####
Bolar, the subject of a criminal investigation by the FDA and the Inspector General's office of the Health and Human Services Department, only agreed to recall two strengths of its version of Macrodantin "as far down as direct customers, mostly wholesalers
##############
#### Features ####
Ot, Comm, Null, Null
970..985
5,1;5,2;5,3;5,4;5,5
#### Text ####
Mr. Nesbit said
##############
____Arg2____
989..1012;1023..1111
6,0;6,2;6,3
#### Text ####
Bolar, of Copiague, N.Y began a voluntary recall of both its 100 milligram and 50 milligram versions of the drug
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1320
8
#### Features ####
Wr, Comm, Null, Null
however, Comparison.Contrast
____Arg1____
1132..1318
7,1,1,1
#### Text ####
it presented evidence it uncovered to the company indicating that Bolar substituted the brand-name product for its own to gain government approval to sell generic versions of Macrodantin
##############
#### Features ####
Ot, Comm, Null, Null
1115..1131
7,0;7,1,0;7,1,1,0;7,2
#### Text ####
The FDA has said
##############
____Arg2____
1320..1404
8
#### Text ####
Bolar has denied that it switched the brand-name product for its own in such testing
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
